36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

Completed

Conditions studied: Meningitis, Meningococcal Disease

In brief

To further characterize the safety profile of Menactra vaccine and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.

Key facts

Study ID

NCT00728260

Run by

Sanofi Pasteur, a Sanofi Company

People needed

1421

Starts

2005-07-01

Expected to finish

2013-05-01

Last updated by the study team

2015-02-12

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Receipt of Menactra vaccine during the study period.

You may not qualify if…

• None

Where it is running

• Study site — Oakland, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.